Indoco Remedies - Growth Prospects Attractive: Nirmal Bang
The company aspires to achieve Rs 50 billion revenue in less than five years through both organic as well as inorganic routes.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We hosted the Indoco Remedies Ltd.'s management at our Annual Investor Conference to discuss the company’s future business outlook.
Indoco Remedies expects the U.S. and European markets to continue to deliver strong growth on the back of robust order book of Rs 1.5 billion each and margin expansion.
For India, the management has guided for double-digit market beating growth FY24 onwards, driven by deeper market penetration, market share gains in key segments, new launches, and inorganic opportunities.
Overall, Indoco Remedies aspires to achieve Rs 50 billion revenue (Rs 15 billion in FY22) in less than five years through both organic as well as inorganic routes.
On the margin front, it expects 23-24% Ebitda margin in the next three years.
We remain positive about the company’s future growth prospects mainly due to high domestic contribution, robust complex products portfolio for the export markets and reasonable valuation.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.